AMIA’s goal is to improve the legislative and regulatory environment for health informatics research, practice and education through AMIA member expertise. The primary pathway through which AMIA achieves this goal is by engaging Federal Agencies and Congress on public calls for input, such as Notices of Proposed Rulemakings (NPRMs) or Request for Information (RFIs).
Learn more about the comment process
AMIA responses are arranged by Federal Agency and Congressional Committee.
AMIA provided comments to The White House Office of Science and Technology Policy (OSTP) Request for Information on Clinical Research Infrastructure and Emergency Clinical Trials. AMIA commends OSTP for its focus on efforts to protect the public health in cases of national emergency. An established research infrastructure, uniform protocol […]
The American Medical Informatics Association (AMIA) appreciates the opportunity to provide input to the Centers for Medicare and Medicaid Services (CMS) Request for Information: National Directory of Healthcare Providers & Services. AMIA commends CMS for soliciting input on the concept of establishing a National Directory of Healthcare Providers & Services […]
In response to a request for public feedback on a set of draft developer-reported measures for the Electronic Health Record Reporting Program, AMIA recommended elevating an additional public health-focused measure to the first set of measures for the program. AMIA additionally recommended that and EHR safety measure that leverages […]
In response to a Request for Information from the National Institutes of Health (NIH), AMIA strongly supported additional research on whether telehealth can support initiatives related to suicide risk reduction and opioid overdose prevention. NIH was seeking input on current clinical experience in the use of telehealth in emergency department […]
In comments submitted to officials from four federal agencies, AMIA supported the continued development of the Federal Data Strategy. AMIA reiterated the support that it lent to the first draft Strategy in 2018, while making several additional recommendations, including the creation of an OMB Data Council, the development of […]
In comments submitted this week to the U.S. Food and Drug Administration (FDA), the nation’s informatics professionals applauded the agency for developing a regulatory Modification Framework for Artificial Intelligence (AI)/Machine Learning (ML)-based software as a medical device (SaMD). The American Medical Informatics Association (AMIA) offered additional observations and recommendations for […]
In response to a Request for Information from the Centers for Disease Control and Prevention, AMIA urged HHS officials to focus on narrow use cases, such as CDS or eCQMs, when conceptualizing a national collaborative for health IT testing. AMIA also outlined the pros/cons of focusing on CDS versus eCQMs […]
AMIA strongly encouraged the Trump administration to leverage an existing strategy on Artificial Intelligence Research and Development (AI R&D), rather than begin from scratch. It additionally emphasized a need for federal investments in areas of strong societal importance not aimed at consumer markets, especially related to human-AI collaboration and the […]
In comments submitted to the Office of the National Coordinator for Health IT (ONC), the AMIA questioned the constrained scope of the EHR Reporting Program, strongly recommending that it measure performance to improve CEHRT security, interoperability, and usability, and not be used simply to provide data for “acquisition decision makers.”
AMIA responded to an FDA request for input with a preliminary review of relevant research into the specific benefits and risks to health associated with software functions that the 21st Century Cures Act excluded from the definition of medical device. While some health IT applications to healthcare delivery have unambiguously […]